Linus Health
Linus Health has developed a digital cognitive assessment platform that utilizes AI to enhance traditional cognitive tests, enabling the early detection of Alzheimer’s and other dementias. This platform provides actionable clinical insights, addressing the critical gap in timely diagnosis and intervention for cognitive health issues.
- Artificial Intelligence
- Digital Health
- Healthcare Technology
- Software Only
Funding
Raised to date
$64.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alzheimer's and other dementias often go undetected until overt symptoms arise, which can be 15-20 years after the initial pathology develops. Traditional cognitive testing methods are outdated and impractical, hindering early detection and intervention in brain health. The demand for neurologists is projected to exceed supply by 19% by 2025, further complicating timely diagnosis and care.
Solution
Linus Health offers a digital cognitive assessment platform that leverages AI to improve the detection of early-stage Alzheimer's and other dementias. The platform enhances traditional cognitive tests, providing clinicians with actionable insights for timely diagnosis and intervention. By applying AI to long-trusted cognitive tests, the platform delivers rich insights and actionable clinical guidance. The solution aims to provide an efficient, scientifically-validated method for detecting early signs of cognitive impairment, opening a new window of opportunity for action.
Target Audience
The primary users are healthcare providers looking to detect and address cognitive issues early, and life science organizations seeking to enhance and streamline cognitive studies.
Features
- AI-enhanced digital cognitive assessments based on proven science.
- Platform detects subtle signs of cognitive impairment.
- Technology validated in over 20 published studies.
- Sensitive in detecting early signs of cognitive impairment.
- Association with key Alzheimer’s biomarkers.